Protocol Ledger

Biopharma Industry · Consolidated Sponsor Hub

Immunovant Sciences: Clinical Trials & FDA Approval Profile

Immunovant Sciences (Global / Institutional) sponsors 19 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 8 active protocols (5 recruiting now), 5 completed protocols, and 0 all-time original FDA Drugs@FDA NDA and BLA approvals.

Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)31.6%
Median Closed Enrollment vs National (145 pts)65 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for Immunovant Sciences
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)19
Active Pipeline (Recruiting Now)8 (5)
Completed vs Stopped Early5 / 6 (31.6%)
Median Closed Actual Enrollment65 participants
Physical Hospital Site Disclosure100.0% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals0 (0 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With Immunovant Sciences
Hospital Research SiteLocationShared Protocols
University of Michigan Rogel Cancer CenterAnn Arbor, MI2

Indexed Multi-Center Phase II & III Protocols

Representative ClinicalTrials.gov v2 Studies Sponsored by Immunovant Sciences
NCT IdentifierProtocol Brief TitlePhaseStatus
NCT03938545ASCEND GO-2: Study of RVT-1401 for the Treatment of Participants With Active, Moderate to Severe Graves' Ophthalmopathy ( GO )Phase IITERMINATED

Explore interactive annual charts and M&A subsidiary rollups in the Immunovant Sciences Interactive Dossier, benchmark peers in Immunology, Rheumatology, and Dermatology, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI